Technology | March 28, 2014

FDA Clears World’s First Implantable Sensor to Measure Radiation Dose Directly at Tumor Site

VeriTeQ’s radiation dosimetry products already have six FDA clearances and CE approvals

Q Inside SmartMarker Vertiq Corp. Radiation Dose Management Radiation Therapy

March 28, 2014 — VeriTeQ Corp. is rebranding its Q Inside SmartMarker to lead its radiation dosimetry business. Q Inside SmartMarker (previously known as DVS SmartMarker) is the only U.S. Food and Drug Administration (FDA)-cleared implantable radio frequency (RF) radiation sensor that provides localization of a tumor and measures radiation dose at the tumor site. VeriTeQ’s radiation dosimetry products have six FDA clearances and CE approvals, and the company has more than 100 patents, patents pending and exclusive licenses.

Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician’s plan, as even a small deviation from planned dose can have a significant impact on patient survival rates.

Scott R. Silverman, chairman and CEO of VeriTeQ, stated, “Radiation under-dosing and, perhaps more importantly, radiation overdosing have been a top concern of the medical community for years. Confirming the delivered dose of radiation is known to have a direct and significant impact on treatment efficacy and patient survival rates, and our Q Inside SmartMarker can support healthcare providers with this potentially life-saving data.”

According to the ECRI Institute, radiation or computed tomography (CT) overdose make the list of the Top 10 Technology Hazards each year going back at least eight years. These hazards include radiation overdose and other errors during radiation therapy; unnecessary exposures and radiation burns from diagnostic radiology procedures; and exposure hazards from radiation therapy and CT.

Q Inside SmartMarker is compatible with a variety of commercially available systems including, but not limited to, CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens MV CBCT and Resonant Medical.

For more information: www.veriteqcorp.com

Related Content

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Veterans Integrated Service Network 19 Implements System-Wide Radiation Dose Monitoring
News | Radiation Dose Management | December 04, 2018
Agfa HealthCare announced it has collaborated in delivering a system-wide DoseMonitor automated software implementation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...